Cellectis (CLLS) Capital Expenditures Growth (3y) (2018 - 2026)
Cellectis (CLLS) Capital Expenditures Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -12.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -7.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.55% |
| Dec 31, 2025 | -1.37% |
| Sep 30, 2025 | -38.14% |
| Jun 30, 2025 | 30.66% |
| Mar 31, 2025 | 14.23% |
| Dec 31, 2024 | -49.94% |
| Sep 30, 2024 | 44.77% |
| Jun 30, 2024 | 42.46% |
| Mar 31, 2024 | 70.14% |
| Dec 31, 2023 | -70.43% |
| Sep 30, 2023 | 63.27% |
| Jun 30, 2023 | 73.17% |
| Mar 31, 2023 | 70.03% |
| Dec 31, 2022 | -42.45% |
| Sep 30, 2022 | 56.56% |
| Jun 30, 2022 | 32.68% |
| Mar 31, 2022 | 29.83% |
| Dec 31, 2021 | 72.78% |
| Sep 30, 2021 | -55.24% |
| Jun 30, 2021 | -114.66% |